A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer

Trial Profile

A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ALTER0303
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 06 Jun 2017 Results (n=49) assessing association between activated circulating endothelial cells and PFS, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Primary endpoint (Overall Survival (OS)) has been met, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top